- Home
- SCLXW vs PVBC Comparison
SCLXW vs PVBC Comparison
Compare SCLXW & PVBC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCLXW
- PVBC
- Stock Information
- Founded
- SCLXW N/A
- PVBC 1913
- Country
- SCLXW United States
- PVBC United States
- Employees
- SCLXW 115
- PVBC N/A
- Industry
- SCLXW Biotechnology: Pharmaceutical Preparations
- PVBC Major Banks
- Sector
- SCLXW Health Care
- PVBC Finance
- Exchange
- SCLXW Nasdaq
- PVBC Nasdaq
- Market Cap
- SCLXW N/A
- PVBC N/A
- IPO Year
- SCLXW N/A
- PVBC 2015
- Fundamental
- Price
- SCLXW $0.10
- PVBC $11.38
- Analyst Decision
- SCLXW
- PVBC Hold
- Analyst Count
- SCLXW 0
- PVBC 1
- Target Price
- SCLXW N/A
- PVBC $12.50
- AVG Volume (30 Days)
- SCLXW 4.0K
- PVBC 30.2K
- Earning Date
- SCLXW 03-07-2025
- PVBC 07-28-2025
- Dividend Yield
- SCLXW N/A
- PVBC N/A
- EPS Growth
- SCLXW N/A
- PVBC N/A
- EPS
- SCLXW N/A
- PVBC 0.26
- Revenue
- SCLXW $55,152,000.00
- PVBC $50,244,000.00
- Revenue This Year
- SCLXW N/A
- PVBC $9.73
- Revenue Next Year
- SCLXW N/A
- PVBC $4.87
- P/E Ratio
- SCLXW N/A
- PVBC $43.23
- Revenue Growth
- SCLXW 22.02
- PVBC N/A
- 52 Week Low
- SCLXW $0.18
- PVBC $9.48
- 52 Week High
- SCLXW $0.18
- PVBC $12.96
- Technical
- Relative Strength Index (RSI)
- SCLXW N/A
- PVBC 55.86
- Support Level
- SCLXW N/A
- PVBC $10.94
- Resistance Level
- SCLXW N/A
- PVBC $11.65
- Average True Range (ATR)
- SCLXW 0.00
- PVBC 0.23
- MACD
- SCLXW 0.00
- PVBC 0.03
- Stochastic Oscillator
- SCLXW 0.00
- PVBC 62.24
About SCLXW Scilex Holding Company
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.